New strategies against drug resistance to herpes simplex virus

被引：182
作者：
Jiang, Yu-Chen [1 ]
Feng, Hui [2 ]
Lin, Yu-Chun [1 ]
Guo, Xiu-Rong [3 ,4 ]
机构：
[1] Sichuan Univ, West China Sch Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China
[2] Cent S Univ, XiangYa Stomatol Hosp, Changsha 410078, Peoples R China
[3] Ctr Nanotechnol, Munster, Germany
[4] Sichuan Univ, West China Med Sch, Inst Nanobiomed Technol & Membrane Biol, Chengdu 610041, Peoples R China
来源：
INTERNATIONAL JOURNAL OF ORAL SCIENCE | 2016年 / 8卷 / 01期
关键词：
new strategies; drug resistance; herpes simplex virus; Janus-type nucleoside analogues; lethal mutagenesis; HELICASE-PRIMASE INHIBITOR; NEW-ZEALAND SPONGE; ACYCLOVIR-RESISTANT; THYMIDINE KINASE; ANTIVIRAL ACTIVITY; GENITAL HERPES; JANUS-TYPE; TRANSPLANT RECIPIENTS; LETHAL MUTAGENESIS; DNA-POLYMERASE;
D O I：
10.1038/ijos.2016.3
中图分类号：
R78 [口腔科学];
学科分类号：
1003 ;
摘要：
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a significant human pathogen that results in mucocutaneous lesions in the oral cavity or genital infections. Acyclovir (ACV) and related nucleoside analogues can, successfully treat HSV infections, but the emergence of drug resistance to ACV has created a barrier for the treatment of HSV infections, especially in immunocompromised patients. There is an urgent need to explore new and effective tactics to circumvent drug resistance to HSV. This review summarises the current strategies in the development of new targets (the DNA helicase/primase (H/P) complex), new types of molecules (nature products) and new antiviral mechanisms (lethal mutagenesis of Janus-type nucleosides) to fight the drug resistance of HSV.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 108 条
[1]   Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals [J].
Aichelburg, Maximilian C. ;
Weseslindtner, Lukas ;
Mandorfer, Mattias ;
Strassl, Robert ;
Rieger, Armin ;
Reiberger, Thomas ;
Puchhammer-Stoeckl, Elisabeth ;
Grabmeier-Pfistershammer, Katharina .
PLOS ONE, 2015, 10 (08)
[2]   In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs [J].
Andrei, G. ;
Topalis, D. ;
Fiten, P. ;
McGuigan, C. ;
Balzarini, J. ;
Opdenakker, G. ;
Snoeck, R. .
JOURNAL OF VIROLOGY, 2012, 86 (05) :2641-2652
[3]  
[Anonymous], 2007, EXPERT REV ANTI-INFE, V5, P540
[4]   Adoptive Transfer of EBV Specific CD8+ T Cell Clones Can Transiently Control EBV Infection in Humanized Mice [J].
Antsiferova, Olga ;
Mueller, Anne ;
Raemer, Patrick C. ;
Chijioke, Obinna ;
Chatterjee, Bithi ;
Raykova, Ana ;
Planas, Raquel ;
Sospedra, Mireia ;
Shumilov, Anatoliy ;
Tsai, Ming-Han ;
Delecluse, Henri-Jacques ;
Muenz, Christian .
PLOS PATHOGENS, 2014, 10 (08)
[5]  
Astellas A, 2013, PHASE 1 RANDOMIZED D
[6]   Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy [J].
Bacon, TH ;
Levin, MJ ;
Leary, JJ ;
Sarisky, RT ;
Sutton, D .
CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) :114-+
[7]  
Baumeister Judith, 2007, Antiviral Chemistry & Chemotherapy, V18, P35
[8]   Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir and oral valganciclovir [J].
Bedel, Ashley N. ;
Hemmelgarn, Trina S. ;
Kohli, Rohit .
LIVER TRANSPLANTATION, 2012, 18 (03) :347-354
[9]   Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293 [J].
Betz, UAK ;
Fischer, R ;
Kleymann, G ;
Hendrix, M ;
Rübsamen-Waigmann, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1766-1772
[10]   The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1 [J].
Biswas, Subhajit ;
Jennens, Lyn ;
Field, Hugh J. .
ANTIVIRAL RESEARCH, 2007, 75 (01) :30-35
12345678910